Drugs / EMVODODSTAT
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03761069 | Oct 2018 → Dec 2021 | acute myeloid leukemia | PTC Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT01158300 | Nov 2010 → Jan 2015 | central nervous system neoplasm | Pediatric Brain Tumor Consortium | Completed | No outcome recorded |
| Phase 1 | NCT00704821 | Jul 2008 → Feb 2012 | — | PTC Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT00508586 | Nov 2007 → Mar 2012 | breast cancer | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00686842 | Sep 2008 → Nov 2010 | Kaposi's sarcoma | AIDS Malignancy Consortium | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00911248 | Jul 2009 → Mar 2012 | NF2-related schwannomatosis | PTC Therapeutics | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04439071 | Jul 2020 → Jul 2022 | COVID-19, pneumonia | PTC Therapeutics | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMVODODSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650336 ↗ |
| Known as | PTC299 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04439071 ↗ |
| Action | Inhibit | “Dihydroorotate dehydrogenase inhibitor” CHEMBL4650336 ↗1“decrease production of VEGF” NCT00508586 ↗ |
| Modality | Small molecule | “anti-VEGF small molecule PTC299” NCT00686842 ↗ |
| Route | Oral | “PTC299 is an oral drug” NCT00508586 ↗ |
| Target | DHODH | “Dihydroorotate dehydrogenase inhibitor” CHEMBL4650336 ↗ |